<SEC-DOCUMENT>0001558370-19-000152.txt : 20190115
<SEC-HEADER>0001558370-19-000152.hdr.sgml : 20190115
<ACCEPTANCE-DATETIME>20190115091630
ACCESSION NUMBER:		0001558370-19-000152
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190115
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190115
DATE AS OF CHANGE:		20190115

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AxoGen, Inc.
		CENTRAL INDEX KEY:			0000805928
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				411301878
		STATE OF INCORPORATION:			MN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36046
		FILM NUMBER:		19526293

	BUSINESS ADDRESS:	
		STREET 1:		13631 PROGRESS BLVD.
		STREET 2:		SUITE 400
		CITY:			ALACHUA
		STATE:			FL
		ZIP:			32615
		BUSINESS PHONE:		(386) 462-6817

	MAIL ADDRESS:	
		STREET 1:		13631 PROGRESS BLVD.
		STREET 2:		SUITE 400
		CITY:			ALACHUA
		STATE:			FL
		ZIP:			32615

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LECTEC CORP /MN/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>axgn-20190115x8k.htm
<DESCRIPTION>8-K
<TEXT>
<!--HTML document created with Merrill Bridge  8.3.0.54-->
<!--Created on: 1/15/2019 8:14:35 AM-->
<html>
	<head>
		<title>
			axgn_20190115_8K
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt;border-top:3pt solid #000000 ;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt solid #000000 ;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;">UNITED STATES</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:12pt;">SECURITIES AND EXCHANGE COMMISSION</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">Washington, D.C. 20549</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 16pt;">
			<font style="display:inline;font-size:16pt;">Form 8-K</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-weight:bold;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">Current Report</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of&nbsp;1934</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">Date of Report (Date of earliest event reported): January 15, 2019</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 16pt;">
			<font style="display:inline;font-size:16pt;">AXOGEN, INC</font><font style="display:inline;">.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">(</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Exact name of registrant as specified in its charter)</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:31.38%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">Minnesota</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.10%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:35.60%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">001-36046</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.10%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:28.84%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">41-1301878</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:31.38%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">(State or other jurisdiction of</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.10%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:35.60%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">(Commission&nbsp;File&nbsp;Number)</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.10%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:28.84%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">(IRS Employer Identification&nbsp;No.)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:31.38%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">incorporation)</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:02.10%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:35.60%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:02.10%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:28.84%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:50.22%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">13631 Progress Boulevard, Suite 400,</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.14%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:47.64%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:50.22%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">Alachua,&nbsp;Florida </font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.14%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:47.64%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">32615</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:50.22%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">(Address of Principal&nbsp;Executive&nbsp;Offices)</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:02.14%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:47.64%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">(Zip Code)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Registrant&#x2019;s telephone number, including area code</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:100.00%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">(386) 462-6800</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:100.00%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">(Former name or former address if changed since last report,)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&#x2610;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;&nbsp;&nbsp;&nbsp;Written&nbsp;communications&nbsp;pursuant&nbsp;to&nbsp;Rule&nbsp;425&nbsp;under&nbsp;the&nbsp;Securities&nbsp;Act&nbsp;(17&nbsp;CFR&nbsp;230.425)</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&#x2610;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;&nbsp;&nbsp;&nbsp;Soliciting&nbsp;material&nbsp;pursuant&nbsp;to&nbsp;Rule&nbsp;14a-12&nbsp;under&nbsp;the&nbsp;Exchange&nbsp;Act&nbsp;(17&nbsp;CFR&nbsp;240.14a-12)</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&#x2610;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&#x2610;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#xA7;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#xA7;240.12b-2 of this chapter).</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Emerging growth company </font><font style="display:inline;color:#000000;font-size:9pt;">&#x2610;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="display:inline;color:#000000;font-size:9pt;">&#x2610;</font>
		</p>
		<p style="margin:0.05pt 0pt 0pt;border-bottom:1pt solid #000000 ;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:3pt solid #000000 ;font-family:Calibri;font-size: 1pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0.2pt 0pt 0pt;font-family:Calibri;font-size: 5pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:5.5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 11pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 11pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Calibri;font-size: 11pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">Item 8.01&nbsp;Other Events</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">On January 15, 2019, AxoGen, Inc. (the &#x201C;Company&#x201D;) issued a press release announcing information regarding the Company&#x2019;s RECON</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;"> study which supports its Biologic License Application Submission for Avance</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;"> Nerve &nbsp;Graft. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">Item 9.01. Financial Statements and Exhibits</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;height:1.00pt;overflow:hidden;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">P</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:83.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:15.00%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Exhibit&nbsp;No.</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:83.00%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Description</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:15.00%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">99.1</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:02.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:83.00%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<a href="axgn-20190115ex99168eb80.htm"><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">AxoGen, Inc. Press Release, dated January 15, 2019.</font></a></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 7pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:7pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 11pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Calibri;font-size: 11pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">EXHIBIT INDEX</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:15.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:83.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:15.00%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Exhibit&nbsp;No.</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:83.00%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Description</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:15.00%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">99.1</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:02.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:83.00%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<a href="axgn-20190115ex99168eb80.htm"><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">AxoGen, Inc. Press Release, dated January 15, 2019.</font></a></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 11pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Calibri;font-size: 11pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:9pt;">SIGNATURE</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Calibri;font-size: 9pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:49.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:47.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.98%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.02%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">AXOGEN, INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.98%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:50.02%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.98%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Date: January&nbsp;15,&nbsp;2019</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.86%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">By: </font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:47.16%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">/s/ Gregory&nbsp;G.&nbsp;Freitag</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.98%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.86%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:47.16%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">Gregory G.&nbsp;Freitag</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.98%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.86%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:47.16%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">General Counsel</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:49.98%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:02.86%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:47.16%;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;font-size: 9pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Calibri;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>axgn-20190115ex99168eb80.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--HTML document created with Merrill Bridge  8.3.0.54-->
<!--Created on: 1/15/2019 8:14:40 AM-->
<html>
	<head>
		<title>
			Exhibit 991
		</title>
	</head>
	<body><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p style="margin:0pt;text-align:right;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 14pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-size:14pt;">Exhibit 99.1</font>
		</p>
		<p style="margin:0pt;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;"><img src="axgn20190115ex99168eb80001.jpg" style="width: 2.127388in; height: 0.6775525in" alt="axogen-inc-logo.jpg"></font>
		</p>
		<p style="margin:0pt;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-weight:bold;font-size:11pt;display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 16pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:16pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 63pt 0pt 58.5pt;line-height:115%;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 16pt;">
			<font style="font-family:Calibri;font-weight:bold;font-size:14pt;display:inline;font-family:Calibri;font-size:16pt;">AxoGen Announces RECON</font><font style="font-family:Calibri;font-weight:bold;font-size:14pt;display:inline;font-family:Calibri;">&#xAE;</font><font style="font-family:Calibri;font-weight:bold;font-size:14pt;display:inline;font-family:Calibri;font-size:16pt;"> Study Update&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;font-size:11pt;display:inline;font-style:italic;">Study Supports Company&#x2019;s&nbsp;Planned Biologic License Application (BLA) for Avance<a name="_Hlk535258438"></a></font><font style="font-family:Calibri;display:inline;font-size:11pt;">&#xAE;</font><font style="font-family:Calibri;font-size:11pt;display:inline;font-style:italic;"> Nerve Graft</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:5pt 0pt;line-height:115%;border-bottom:1pt none #D9D9D9 ;text-align:left;font-family:Calibri;punctuation-wrap:word-break;text-justify:inter-ideograph;font-size: 14pt;">
			<font style="font-family:Calibri;font-weight:bold;font-size:14pt;display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">&nbsp;</font><font style="font-family:Calibri;font-weight:bold;font-size:11pt;display:inline;">ALACHUA, FL &#x2013; January 15, 2019 &#x2013; </font><font style="font-family:Calibri;font-size:11pt;display:inline;">AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for </font><font style="display:inline;">damage or discontinuity to peripheral nerves</font><font style="font-family:Calibri;font-size:11pt;display:inline;">, today <a name="_Hlk534358337"></a>announced that the RECON</font><font style="font-family:Calibri;display:inline;">&#xAE;</font><font style="font-family:Calibri;font-size:11pt;display:inline;"> Study supporting its Biologic License Application (BLA) Submission for Avance&#xAE; Nerve Graft has reached its current enrollment milestone of 170 subjects.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:115%;border-top:1pt none #D9D9D9 ;text-align:left;font-family:Calibri;punctuation-wrap:word-break;text-justify:inter-ideograph;font-size: 11pt;">
			<font style="font-family:Calibri;font-size:11pt;display:inline;">RECON</font><font style="font-family:Calibri;display:inline;">&#xAE;</font><font style="font-family:Calibri;font-size:11pt;display:inline;"> is AxoGen&#x2019;s phase three pivotal study comparing Avance&#xAE; Nerve Graft to manufactured cond<a name="_Hlk534465803"></a>uits. </font><font style="display:inline;">The study requires a one year follow up period for all subjects and is designed to assess return of sensation in digital nerve injuries, quality of life outcomes, and subject satisfaction. &nbsp;The FDA-approved statistical analysis plan was designed with an interim blinded analysis&nbsp;to provide a safeguard for the assumptions used in the design of the protocol. It is possible to increase&nbsp;the study sample size to maintain the original power of the study in the event the pooled variance of the standard deviation, a key statistical assumption in the power analysis, is not consistent with the original assumptions. This interim analysis is designed to protect the validity and integrity of the study. &nbsp;AxoGen has submitted the interim analysis to the FDA for review with the intention of obtaining agreement on next steps, which could include continuing&nbsp;study enrollment. The Company will provide further updates upon completion of the review, the timing of which is uncertain based upon near-term funding issues faced by the FDA.&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;display:inline;font-size:11pt;">&#x201C;We are pleased to have achieved this important enrollment milestone, which we could not have reached without the dedication and commitment of each of the participating study teams,&#x201D; said Karen Zaderej, chairman, CEO, and president of AxoGen. &#x201C;We have been working diligently to transition our nerve graft from classification as a 361 HCT/P tissue product to a biologic product. The RECON&#xAE; study is a critical step in this transition process.&#x201D;</font><font style="font-family:Calibri;display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="font-family:Calibri;display:inline;font-size:11pt;">In September 2018 the FDA granted a Regenerative Medicine Advance Therapy (RMAT) &nbsp;designation for Avance&#xAE; Nerve Graft. A regenerative medicine therapy is eligible for the designation if it is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product has the potential to address unmet medical needs for such a disease or condition. The RMAT designation provides access to a streamlined approval process for regenerative medicine technologies and ensures continued informal meetings with the FDA in support of the BLA for Avance&#xAE; Nerve Graft. </font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;border-top:1pt none #D9D9D9 ;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">About AxoGen</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">AxoGen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate </font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><p style="margin:0pt;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;"><font style="display:inline;font-family:Calibri;font-size:11pt;">about helping to restore peripheral nerve function and quality of life to patients with physical damage or discontinuity to peripheral nerves by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves.&nbsp;Physical damage to a peripheral nerve,</font><font style="display:inline;font-family:Calibri;">&nbsp;</font><font style="display:inline;font-family:Calibri;font-size:11pt;">or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. </font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">AxoGen's platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance</font><font style="display:inline;font-family:Calibri;font-size:11pt;font-size:6pt;top:-4.4pt;position:relative;line-height:115%">&#xAE;</font><font style="display:inline;font-family:Calibri;font-size:11pt;"> Nerve Graft, a biologically active off-the-shelf&nbsp; processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard</font><font style="display:inline;font-family:Calibri;font-size:11pt;font-size:6pt;top:-4.4pt;position:relative;line-height:115%">&#xAE;</font><font style="display:inline;font-family:Calibri;font-size:11pt;"> Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard</font><font style="display:inline;font-family:Calibri;font-size:11pt;font-size:6pt;top:-4.4pt;position:relative;line-height:115%">&#xAE;</font><font style="display:inline;font-family:Calibri;font-size:11pt;"> Nerve Protector, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; and Avive</font><font style="display:inline;font-family:Calibri;font-size:11pt;font-size:6pt;top:-4.4pt;position:relative;line-height:115%">&#xAE;</font><font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;Soft Tissue Membrane, a minimally processed human umbilical cord membrane that may be used as a resorbable soft tissue covering to separate tissue layers and modulate inflammation in the surgical bed. Along with these core surgical products, AxoGen also offers AcroVal</font><font style="display:inline;font-family:Calibri;font-size:11pt;font-size:6pt;top:-4.4pt;position:relative;line-height:115%">&#xAE;</font><font style="display:inline;font-family:Calibri;font-size:11pt;"> Neurosensory &amp; Motor Testing System and AxoTouch</font><font style="display:inline;font-family:Calibri;font-size:11pt;font-size:6pt;top:-4.4pt;position:relative;line-height:115%">&#xAE;</font><font style="display:inline;font-family:Calibri;font-size:11pt;"> Two-Point Discriminator. These evaluation and measurement tools assist health care professionals in detecting changes in sensation, assessing return of sensory, grip, and pinch function, evaluating effective treatment interventions, and providing feedback to patients on peripheral nerve function. The AxoGen portfolio of products is available in the United States, Canada, the United Kingdom, and several other European and international countries.</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">Cautionary Statements Concerning Forward-Looking Statements<br /></font><font style="display:inline;font-family:Calibri;font-size:11pt;">This Press Release contains &#x201C;forward-looking&#x201D; statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events, or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as &#x201C;expects,&#x201D; &#x201C;anticipates,&#x201D; &#x201C;intends,&#x201D; &#x201C;plans,&#x201D; &#x201C;believes,&#x201D; &#x201C;seeks,&#x201D; &#x201C;estimates,&#x201D; &#x201C;projects,&#x201D; &#x201C;forecasts,&#x201D; &#x201C;continue,&#x201D; &#x201C;may,&#x201D; &#x201C;should,&#x201D; &#x201C;will,&#x201D; and variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our assessment on our internal control over financial reporting, our growth, our 2018 and 2019 guidance, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our visibility at and sponsorship of conferences and educational events. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events, or otherwise.</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9;border-left:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;border-right:1pt none #D9D9D9;line-height:115%;border-bottom-style:solid;border-bottom-width:1pt;font-family:Calibri;color:#000000;punctuation-wrap:word-break;text-align:justify;text-justify:inter-ideograph;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;punctuation-wrap:word-break;text-align:justify;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><p style="margin:0pt;punctuation-wrap:word-break;text-align:justify;text-justify:inter-ideograph;font-family:Batang;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;line-height:115%;punctuation-wrap:word-break;text-align:justify;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;font-size:11pt;">Contacts:</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">AxoGen, Inc.</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Kaila Krum, VP, Investor Relations and Corporate Development</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">kkrum@AxoGenInc.com</font><font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Solebury Trout</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Brian Korb </font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">646.378.2923</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">bkorb@troutgroup.com</font><font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:left;text-decoration:underline;font-family:Arial,Helvetica,sans-serif;punctuation-wrap:word-break;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:115%;text-align:left;color:#0000FF;punctuation-wrap:word-break;text-justify:inter-ideograph;font-family:Batang;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font>
		</p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;">
		<p><font size="1"> </font></p></div><div style="margin-left:11.7647058823529%;margin-right:11.7647058823529%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>axgn20190115ex99168eb80001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 axgn20190115ex99168eb80001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "5 =0# 2(  A$! Q$!_\0
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M8L/DE5=9VBOF]?P3/H_"?+7B^):#MI3YIOY*R_\ )FCZRHHHK^:S^T HHHH
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M*6EF/]I\<MZ*N6/IC)'U/\&O^"5.B_#[26\2?%OQ!9BSL4\^>QMIS#:Q*/\
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M/$.M74/EZIXR<7[DCYEMP"(%^A4LX_ZZU^\\4<01R?!?6$DY-I16U^_R2O\
M@?RKP+PG/B+,_JDI.,$G*4EJTMEOU;:^5WT/SZ_X9A^)7_1//'/_ ((;K_XW
M1_PS#\2O^B>>.?\ P0W7_P ;K]EZ*_-O^(K8O_GQ'[V?L_\ Q ? ?]!4_P#P
M&)^(OC#P%KOP\U&.S\0:+JVAW<T8F2#4+.2UD="2 P5P"5R",],@UDU]A?\
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M2*>#D H _.S]MCX(R>#?VUM4TCRVBL_%6I17]HV,!TNI/FQ])3(O_ :^I/\
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M9;ON^[?5O5A1116)T!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
:444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
